利福昔明-双歧杆菌乳杆菌三联活菌片序贯疗法治疗肠易激综合征的临床观察

目的 探讨利福昔明-双歧杆菌乳杆菌三联活菌片序贯疗法治疗肠易激综合征（IBS）的临床效果.方法 将276例IBS患者随机分为3组,每组各92例,A组（序贯组）采用利福昔明-双歧杆菌乳杆菌三联活菌片序贯治疗＋谷维素；B组（菌剂组）采用双歧杆菌乳杆菌三联活菌片＋谷维素；C组（对照组）采用谷维素治疗;观察3组的治疗效果.结果 序贯组的总有效率为95.65％,显著高于菌剂组和对照组的79.35％、73.91％（P＜0.05）.治疗后序贯组的症状程度评分和症状频率评分为（1.48±0.87）分和（1.39±0.98）分,明显低于菌剂组与对照组的（2.24±1.23）分和（2.28±1.16）分、（2.38±1.13）分和（2.48±1.27）分（P＜0.05）.3组不良反应发生率比较差异无统计学意义（P＞0.05）.结论 利福昔明-双歧杆菌乳杆菌三联活菌片序贯治疗IBS方法简便、疗效显著,可能成为治疗IBS的新方法.

Clinical observation of sequential therapy with rifaximin-live combined bifidobacterium and lactobacillus tablets in the treatment of irritable bowel syndrome

Objective To study the clinical effect of sequential therapy with rifaximin-live combined bifidobacterium and lactobacillus tablets in the treatment of irritable bowel syndrome （IBS）. Methods 276 patients with IBS were ran- domly divided into three groups,each group had 92 cases,group A （sequential group） was given sequential-therapy with rifaximin-live combined bifidobacterium and lactobacillus tablets sequential treatment and oryzanol,group B （bacteria agent group group）treated with live combined bifidobacterium and lactobacillus tablets and oryzanol,group C （control group） treated with oryzanol.The therapeutic effect of three groups were observed. Results The total effective rate in sequential group was 95.65%,significantly higher than 79.35% and 79.35% in bacteria agent group and the control group （P〈0.05）.The symptoms of degree index and frequency of symptoms after treatment in sequential group were （1.48±0.87） scores and （1.39±0.98） scores,significantly lower than （2.24±1.23） scores and （2.28±1.16） scores,（2.38±1.13） scores and （2.48±1.2） scores in the bacteria agent group and control group（P〈0.05）.The incidence of adverse re- actions in three groups were not significant （P〉0.05）. Conclusion The sequential therapy with rifaximin-live combined bifidobacterium and lactobadillus tablets is simple and efficacy significantly in the treatment of IBS,and it may become a new method for treatment of IBS.